ArticleBioengineering (Basel, Switzerland)2026
An IoT-Enabled Modular 3D Bioreactor for Vascular Tissue Engineering: Design, Fabrication, and Biological Validation.
Article in Bioengineering (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Three-dimensional (3D) bioreactor systems are essential for vascular tissue engineering as they provide controlled environments that better mimic physiological conditions compared to static culture systems. In this study, an IoT-enabled modular rotating 3D bioreactor platform was designed, fabricated using Fused Deposition Modeling (FDM), and biologically validated. The system integrates a Wi-Fi-supported ESP8266 controller and a touchscreen human-machine interface (HMI), enabling real-time monitoring and remote operation. Agarose-chitosan-based tubular hydrogel constructs were seeded with human aortic smooth muscle cells (HASMCs) and cultured under dynamic conditions for 14 days. Biocompatibility was assessed using a lactate dehydrogenase (LDH) assay, while cellular distribution and mitochondrial activity were evaluated by confocal microscopy using DAPI and MitoTracker staining. Fluorescence intensity was further quantified using ImageJ, and 3D surface plots were generated to visualize spatial signal distribution. The results demonstrated sustained cell viability with decreasing cytotoxicity over time. Confocal analysis confirmed a homogeneous distribution of cells within the hydrogel matrix, and quantitative fluorescence analysis showed significantly higher MitoTracker intensity compared to DAPI, indicating increased metabolic activity under dynamic conditions. These findings suggest that the developed bioreactor provides a stable, controllable, and effective platform for vascular tissue engineering applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.